Keyphrases
Breast Cancer
68%
Metastatic Breast Cancer
51%
Triple-negative Breast Cancer
50%
Tumor
39%
Endocrine Therapy
28%
Aromatase Inhibitors
24%
Human Epidermal Growth Factor Receptor 2 (HER2)
24%
Estrogen Receptor
22%
Fulvestrant
21%
Postmenopausal Women
21%
Chemotherapy
20%
Neoadjuvant Endocrine Therapy
20%
Patient-derived Xenograft
19%
Estrogen Receptor-positive Breast Cancer
18%
Neoadjuvant
18%
Phase II Trial
17%
Estrogen
16%
Confidence Interval
16%
Pathological Complete Response
14%
Breast Cancer Patients
14%
Estrogen Receptor 1 (ESR1)
14%
Cyclin-dependent Kinase 4/6 Inhibitors
13%
Clinical Trials
13%
Palbociclib
13%
Carboplatin
13%
Cyclin-dependent Kinase 4 (CDK4)
13%
Ki-67
13%
HER2-positive
12%
Hormone Receptor-positive
12%
Circulating Tumor DNA (ctDNA)
12%
ER +
11%
Neoadjuvant Chemotherapy
11%
Neratinib
11%
HER2-negative Breast Cancer
11%
Randomized Phase II Trial
10%
Phase II Study
10%
Trastuzumab
9%
Overall Survival
9%
Progression-free Survival
9%
Anastrozole
9%
Estrogen Receptor-positive Metastatic Breast Cancer
9%
Estrogen Receptor-positive
9%
Resistance Mechanisms
9%
HER2 mutation
9%
Mammalian Target of Rapamycin (mTOR)
8%
PIK3CA mutation
8%
Targeted Treatment
8%
Breast Cancer Treatment
8%
Paclitaxel
8%
Phase I Study
8%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
71%
Metastatic Breast Cancer
59%
Neoplasm
44%
Triple Negative Breast Cancer
30%
Estrogen Receptor
24%
Malignant Neoplasm
24%
Fulvestrant
21%
Endocrine Therapy
21%
Hormone Receptor
19%
Disease
19%
Chemotherapy
19%
Aromatase Inhibitor
17%
Cyclin Dependent Kinase 4
16%
Clinical Trial
16%
Progression Free Survival
15%
Phase II Trials
14%
Carboplatin
13%
Palbociclib
13%
Neratinib
11%
Tumor Growth
10%
Overall Survival
9%
Estrogen Receptor Positive Breast Cancer
9%
Biological Marker
9%
Anastrozole
8%
Trastuzumab
8%
Temsirolimus
8%
Gamma Urogastrone
8%
Epidermal Growth Factor Receptor
7%
Bortezomib
7%
Phosphatidylinositol 3 Kinase
7%
Adverse Event
7%
Circulating Tumor DNA
7%
Paclitaxel
7%
Maximum Tolerated Dose
7%
Cyclin Dependent Kinase 6
7%
Epidermal Growth Factor Receptor 2
7%
Solid Malignant Neoplasm
7%
Pharmacokinetics
6%
Irinotecan
6%
Doxorubicin
6%
Aromatase
6%
Neutropenia
5%
Metastasis
5%
Letrozole
5%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
5%
Capecitabine
5%
Recurrent Disease
5%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
42%
Hormone Therapy
41%
Triple Negative Breast Cancer
38%
Metastatic Breast Cancer
38%
Estrogen Receptor
28%
Malignant Neoplasm
23%
Aromatase Inhibitor
21%
Clinical Trial
19%
Disease
18%
Estrogen Receptor Positive Breast Cancer
14%
Chemotherapy
13%
Neoadjuvant Chemotherapy
12%
Phase II Trials
10%
Targeted Therapy
10%
Oncology
10%
Hormone Receptor
10%
Biological Marker
9%
Cyclin-Dependent Kinase 4
9%
Palbociclib
9%
Aromatase
9%
Carboplatin
8%
Anastrozole
8%
Postmenopause
8%
Fulvestrant
7%
Recurrent Disease
7%
Xenograft
7%
Overall Survival
7%
Metastatic Carcinoma
7%
Circulating Tumor DNA
7%
Treatment Response
7%
Progression Free Survival
7%
Progesterone Receptor
6%
Neratinib
6%
Signal Transduction
6%
CDK4/6 Inhibitor
6%
Adjuvant Chemotherapy
5%
Neoadjuvant Therapy
5%
Clinical Stage
5%
Phosphoinositide 3-Kinase
5%
Letrozole
5%
Mammalian Target of Rapamycin
5%
Tumor Progression
5%
Capecitabine
5%